Current maintenance or controller treatments for COPD include tiotropoium, LAMA, LABA, LABA + ICS, LAMA + LABA, roflumilast, theophylline, and 'triple therapy' combining LAMA + LABA + ICS.

in moderate-to-severe COPD. In the study Spiolto - which combines tiotropium, the active ingredient in Boehringer's LAMA drug Spiriva with LABA olodaterol - demonstrated a 42 percent improved in a ...

The near-term pipeline for COPD has several ICS, LABA and LAMA combinations in development with claims of improved efficacy and better safety profiles. Moreover, the development of more innovative ...

In the CRYSTAL study, patients with moderate COPD who were switched to Ultibro Breezhaler from their previous therapy (LABA+ICS * or LABA or LAMA) experienced superior improvements in lung ...